XPHYTO THERAPEUTICS
Commented by Nico Popp on January 27th, 2022 | 10:13 CET
Valneva, XPhyto, Peloton Interactive: What is next for pandemic stocks?
The pandemic is entering a new phase. Although incidences are rising towards the 1,000 mark, the population is largely relaxing. In the meantime, almost everyone knows someone who has fallen ill; as a rule, the scare is over quickly for those who have been vaccinated. In this article, we look at what this means for the stock market.
ReadCommented by Mario Hose on January 13th, 2022 | 12:01 CET
Stocks offer trading opportunities: BrainChip, TeamViewer, XPhyto
On Thursday, most German indices started trading with negative signs. The DAX is currently trading at 15,989 points, down around 0.25%. The psychological mark of 16,000 points has not held compared to the previous day. The MDAX last traded at 34,874 points (-0.14%), TecDAX at 3,637 points (-0.62%) and SDAX at 16,062 points with 0.13% in the red. In the single stocks, on the other hand, there are exciting developments for the stock traders.
ReadCommented by Armin Schulz on January 12th, 2022 | 13:42 CET
Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?
Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.
ReadCommented by Nico Popp on January 7th, 2022 | 12:51 CET
BioNTech, XPhyto, Valneva: 3 stocks for next week?
Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.
ReadCommented by Carsten Mainitz on December 28th, 2021 | 11:26 CET
Novavax, XPhyto Therapeutics, Bayer - Corona shares for 2022!
The head of the Robert Koch Institute, Lothar Wieler, warned a few days ago that the healthcare system would be overburdened and critical care structures impaired if the feared Omicron wave could not be curbed. This situation illustrates that the pandemic is far from letting us go. Vaccine manufacturers and pharmaceutical companies will continue to benefit. Their shares should also be on the winning side next year.
ReadCommented by Armin Schulz on December 15th, 2021 | 11:35 CET
Valneva, XPhyto Therapeutics, Pfizer - Corona is far from defeated
In an interview, new Health Minister Karl Lauterbach said, "We will not succeed in defeating Corona completely in the foreseeable period." By period, he probably means his term, which is four years. Thus, the hope that arose in the middle of the year related to a quick end by vaccination seems to have been dashed. The new Omicron variant cannot yet be fully assessed. It is causing uncertainty on the stock markets, which puts renewed pressure on companies that have already suffered from Corona. On the other hand, there are also the profiteers who are fighting Corona. Today we analyze three of these potential profiteers.
ReadCommented by Stefan Feulner on November 15th, 2021 | 10:50 CET
Valneva, XPhyto, NanoRepro - Here we go again
Although around 67.4% of the population in Germany is already fully vaccinated, the infection figures are rising to unprecedented heights. The fourth wave with the highly contagious Delta variant is rolling across the republic. This development must be stopped as quickly as possible. In addition to booster vaccinations, politicians are therefore reintroducing citizen testing as a tool against the spread. For diagnostics companies and providers of rapid tests, this means a boom and further increases in earnings, likely to be reflected in stock market valuations in the near future.
ReadCommented by André Will-Laudien on September 10th, 2021 | 12:43 CEST
NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!
So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.
ReadCommented by Stefan Feulner on August 27th, 2021 | 11:53 CEST
BioNTech, XPhyto, Moderna - Boosters for the portfolio
Globally, infection numbers are rising dramatically due to the highly contagious Delta variant. According to the RKI, 12,626 new infections were reported in Germany alone, 4,226 more than a week ago. With the incidence rising above the authoritative level of 35, greater emphasis is again being placed on the rule, vaccinated, recovered or tested. As a result, demand for PCR or rapid tests is skyrocketing. Diagnostic companies, like vaccine producers, are in for a warm cash shower.
ReadCommented by Armin Schulz on August 16th, 2021 | 13:27 CEST
BioNTech, XPhyto Therapeutics, Siemens Healthineers - Corona has triggered a boom
While many companies have suffered greatly from the Corona pandemic, there are also a number of winners. First and foremost, vaccine manufacturers but also diagnostics companies experienced substantial growth rates in sales. Irrespective of Corona, it is increasingly crucial for the healthcare sector to push ahead with digitization, especially in diagnostics. Here, digitization offers the opportunity to significantly increase the quality and speed of diagnoses through artificial intelligence. Time, in particular, is an important factor here. Today, we take a closer look at three beneficiaries of the Corona Crisis.
Read